Synthesis and Biological Evaluation of C-17-Amino-Substituted Pyrazole-Fused Betulinic Acid Derivatives as Novel Agents for Osteoarthritis Treatment

Jie Wang,Wenhui Wei,Xiaofei Zhang,Shiqi Cao,Bintao Hu,Yang Ye,Min Jiang,Tianqi Wang,Jianping Zuo,Shijun He,Chunhao Yang
DOI: https://doi.org/10.1021/acs.jmedchem.1c01019
IF: 8.039
2021-09-07
Journal of Medicinal Chemistry
Abstract:A series of pyrazole-fused betulinic acid (BA) derivatives were designed and synthesized by replacing the carboxyl group at C-17 with aliphatic amine, amide, and urea groups. The suppressive effects of the compounds on osteoclast (OC) formation and inflammatory cytokine production were evaluated on murine macrophages, RAW264.7 cells, conditioned with receptor activator for nuclear factor-κB ligand (RANKL)/macrophage colony stimulating factor (M-CSF) or lipopolysaccharide (LPS), respectively. Results showed that, compared with betulinic acid, most of these compounds exhibited significant improvements in inhibitory potency. Compound 25 exhibited distinguished activities on inhibiting OC differentiation with an IC50 value of 1.86 μM. Meanwhile, compound 25, displaying the most promising suppression on IL-1β secretion from RAW264.7 cells, was further found to possess therapeutic effects in the sodium monoiodoacetate (MIA)-induced osteoarthritis rat model. Dose-dependent benefits were observed in MIA-elicited rats with ameliorated joint pain as well as decreased cartilage damage and bone changes after compound 25 treatment.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01019.Solubility test, characterization (1H NMR spectra and 13C NMR spectra are attached), and HPLC purity control of the selected final compounds (PDF)Molecular formula strings of new compounds (CSV)This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?